Maxim downgraded Citius Pharmaceuticals (CTXR) to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR:
- Citius Pharmaceuticals Reports Q1 2025 Earnings and Strategic Developments
- Citius Pharmaceuticals reports Q2 EPS (11c) vs. (7c) last year
- Citius Pharmaceuticals Poised for Growth with Key Milestones and Promising Product Pipeline
- Citius Pharmaceuticals target adjusted to $4 for split at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today